
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences is well-positioned to continue its rapid progression towards key clinical milestones, as evidenced by the recently reported enrollment of over 85% in its PRECISE-AD study for its Alzheimer's candidate, PMN310. With two pivotal data readouts expected in 2026 - interim data in 2Q26 and top-line data in 4Q26 - ProMIS is on track to provide early validation of its differentiated therapeutic approach, targeting toxic amyloid-beta oligomers while intentionally avoiding plaque, to address neurodegeneration without the safety concerns associated with current therapies. This progress, coupled with a favorable safety profile and a strong balance sheet with ~$15M in cash, makes ProMIS a promising investment opportunity.
Bears say
ProMIS Neurosciences is a clinical-stage biotechnology company with a promising lead anti-amyloid candidate, PMN310, currently in Phase 1b trials for Alzheimer's disease. However, the company's current financials do not show any product revenue, and there are potential risks, including failure to show efficacy or unexpected safety issues. Additionally, the company may need to raise money in the markets until they become cash flow positive. Therefore, the analyst maintains a negative outlook on the stock.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares